Am­gen ex­tends au­toim­mune pact with small Michi­gan biotech

Am­gen is go­ing all in on a three-in­di­ca­tion col­lab­o­ra­tion with an Ann Ar­bor, MI biotech.

The Cal­i­for­nia phar­ma has elect­ed to move for­ward with all three au­toim­mune pro­grams in its $240 mil­lion pact with EVOQ Ther­a­peu­tics, the com­pa­nies said Wednes­day. EVOQ re­ceived an undis­closed mile­stone pay­ment.

The duo ini­tial­ly teamed up in Jan­u­ary 2021. Since then, the start­up from the Uni­ver­si­ty of Michi­gan and Lawrence Liv­er­more Na­tion­al Lab­o­ra­to­ry has al­so al­lied with the non­prof­it JDRF on type 1 di­a­betes and, in re­cent weeks, with Gilead for rheuma­toid arthri­tis and lu­pus.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.